Molecule AI
Molecule AI (Delhi, India) builds MoleculeGEN, an AI-driven SaaS platform for de novo molecule generation, virtual screening, ADMET prediction and lead optimization, serving pharmaceutical, biotech, CRO and academic drug-discovery users. Acquired by Shuttle Pharmaceuticals (NASDAQ:SHPH) in February 2026.
- Company typePrivate
- Founded2023
- HeadquartersNew Delhi, India
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Molecule AI does
Molecule AI (operating name; previously known as KnowDis) is a Delhi-headquartered, India-incorporated private company that builds MoleculeGEN, a SaaS platform applying AI to early-stage pharmaceutical discovery. The platform targets pharmaceutical companies, biotech firms, contract research organizations, academic researchers and individual computational/medicinal chemists, with use cases spanning de novo target-aware molecule generation, virtual screening, ADMET prediction, lead optimization, and molecular dynamics simulation.
The product stack is built on what the company describes as 'Biophysics Meets Deep Learning' — proprietary architectures grounded in biophysics principles and intended to extend beyond protein structure prediction (e.g., AlphaFold) toward end-to-end small-molecule design. Core modules include De Novo Generation (generative molecular design from atomic building blocks), ADMET Prediction (AI models for absorption, distribution, metabolism, excretion and toxicity), Virtual Screening, Lead Optimisation (generative AI for QSAR generation and property optimization), Molecular Dynamics interfaces, and a MoleculeAI Labs preview module for upcoming capabilities. Research is anchored by a collaboration with IIT Delhi (active since February 2023), which produced co-authored work including the TAGMol paper at ICML 2024, and the company holds five pending WIPO patent applications covering novel sulfonylurea/sulfoximineurea derivatives, NLRP3 inhibitors and neuroinflammatory treatments.
The business model is subscription-based SaaS delivered through app.moleculeai.com, combined with a sales-assisted demo motion (Calendly) targeting enterprise accounts. Distribution is positioned as global, though India is the only named operating geography. Molecule AI was acquired by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) for $8 million in February 2026 (following an October 2025 LOI at $10 million), transitioning it into a subsidiary of a US-listed pharmaceutical group; its website remains active.
Molecule AI firmographics
Firmographics- Name
- Molecule AI
- Legal name
- Molecule AI Private Limited
- Website
- https://moleculeai.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Molecule AI (Delhi, India) builds MoleculeGEN, an AI-driven SaaS platform for de novo molecule generation, virtual screening, ADMET prediction and lead optimization, serving pharmaceutical, biotech, CRO and academic drug-discovery users. Acquired by Shuttle Pharmaceuticals (NASDAQ:SHPH) in February 2026.
- Ownership category
- akta.pro rank
Molecule AI industry classification
Industry- Product category
- AI-Driven Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- akta.pro industry
- AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)Cheminformatics & Molecular Modeling / CADDHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Keywords
Where Molecule AI is headquartered
LocationHeadquarters
- HQ city
- New Delhi
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Molecule AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- SaaS Platform Subscription: Molecule GEN is offered as a software-as-a-service (SaaS) platform with subscription-based access. Users can book demos and access the platform through app.moleculeai.com, indicating a subscription/recuring revenue model.
- Platform Usage: The platform offers built-in, tailor-made workflows for rational and AI-based de novo drug design, suggesting usage-based or tiered subscription pricing.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Molecule AI product offering
Product offeringCore offering
Molecule AI develops and sells Molecule GEN, an AI-driven drug discovery SaaS platform offered as a cloud-based subscription product. The platform provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization, ADMET prediction, virtual screening, molecular dynamics simulation, and interactive molecule design tools for pharmaceutical and biotech researchers. It is built on proprietary deep learning architectures grounded in biophysics principles and integrates generative AI, predictive analytics, and computational chemistry into a single end-to-end workflow accessible at app.moleculeai.com.
Product overview
Molecule AI offers Molecule GEN as its primary integrated AI-driven drug discovery SaaS platform, designed for end-to-end therapeutic development. The platform combines multiple modules including De Novo Generation (AI-driven target-aware molecule creation), Virtual Screening (computational chemistry-based molecule sifting), ADMET Prediction (AI-based drug-likeness and toxicity assessment), and Lead Optimisation (generative AI for property optimization). Supporting tools include Molecular Dynamics interfaces, Molecule Design editors, and Utilities for molecular analysis. MoleculeAI Labs provides early access to upcoming features. The platform is built around multidisciplinary teams combining AI experts with computational and medicinal chemists, leveraging biophysics principles and deep learning architectures.
Differentiator
Problem solved
Functional benefit
Brands
- MoleculeGEN: Proprietary AI-powered integrated drug discovery SaaS platform offering de novo molecule generation, virtual screening, ADMET prediction, lead optimization, molecular dynamics, and molecule design tools.
Products and services
- Molecule GEN One-stop, end-to-end AI-driven drug discovery SaaS platform that provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization capabilities. Integrates ADMET prediction, AI-enhanced virtual screening, molecular dynamics simulation, and interactive molecule design tools. Built-in intelligence and heuristics allow researchers of all skill levels to translate research ideas and expedite discovery of new therapeutic candidates for pharmaceutical and biotech companies, contract research organizations, and academic research institutions.
Quantifiable outcome
- Featured in Inc42's '5 AI Startups To Watch' December 2025 series recognizing India's AI innovation
- +1 more outcomes
Companies that use Molecule AI
Customer profileSegments3 records
Ideal customer profiles3 records
Molecule AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Molecule AI partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Shuttle Pharmaceuticals Holdings, Inc.minorShuttle Pharmaceuticals signed a non-binding Letter of Intent to acquire Molecule.ai (Canadian AI firm) for $10 million subject to milestones. The LOI was later converted to a completed acquisition for $8 million.
- IIT DelhicoreKnowDis (parent company of Molecule AI) and IIT-Delhi collaboration for AI-driven antibody design. The partnership focuses on generative AI for drug discovery and has resulted in co-authored publications including TAGMol paper at ICML 2024.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Molecule AI competitors and assessment
Company assessmentEmerging players
- Isomorphic Labs: Alphabet-backed drug discovery company building on DeepMind's protein-structure work for end-to-end small-molecule design; comparable as an emerging AI-first drug discovery venture targeting pharma collaborations, with deeper capital and proprietary protein-modeling lineage.
- CrushBio (Cradle Bio): AI platform focused on protein engineering and biologics design; adjacent emerging player in generative biology for drug discovery, sharing the AI-for-discovery positioning with Molecule AI's platform.
Direct peers
- Insilico Medicine: AI-driven drug discovery company operating the Pharma.AI platform for target identification, de novo generation, and lead optimization; serves the same pharmaceutical and biotech customers with end-to-end generative AI pipelines overlapping Molecule GEN.
- Schrödinger, Inc. Public computational chemistry and molecular simulation platform offering physics-based software (LiveDesign, Maestro) and drug-discovery services; directly competes with Molecule GEN's computational chemistry and lead optimization capabilities for pharma R&D buyers.
- Exscientia: AI-native pharma combining automated drug design with experimental validation; overlaps with Molecule AI's de novo design and lead-to-candidate positioning for pharma and biotech partners.
- XtalPi: AI plus robotics drug discovery platform offering de novo molecule generation and solid-form prediction; comparable to Molecule GEN's de novo generation and ADMET modules, with similar enterprise SaaS plus services model.
- Recursion Pharmaceuticals: Techbio company using AI/ML and high-throughput biology for drug discovery; comparable as a peer in the AI-discovery space targeting similar big-pharma partnerships and pipeline build-out.
- Atomwise: AI small-molecule discovery company using convolutional neural networks for virtual screening and hit identification; directly comparable to Molecule GEN's virtual screening and ADMET prediction modules for pharma discovery programs.
- BenevolentAI: AI drug discovery company combining knowledge graphs with ML for target identification and molecule design; serves pharma partners in the same AI-discovery category with comparable disease-area partnerships.
Broad incumbents
- Dassault Systèmes (BIOVIA): Broad enterprise scientific software portfolio spanning discovery, modeling and lab informatics through BIOVIA; competes with Molecule GEN as part of a much wider life sciences suite serving global pharma R&D.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Molecule AI social profiles
Digital presenceMolecule AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecule AI leadership team
Management profileNumber of profiles
Profiles6 records
Molecule AI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecule AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecule AI
What does Molecule AI do?
Molecule AI develops and sells Molecule GEN, an AI-driven drug discovery SaaS platform offered as a cloud-based subscription product. The platform provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization, ADMET prediction, virtual screening, molecular dynamics simulation, and interactive molecule design tools for pharmaceutical and biotech researchers. It is built on proprietary deep learning architectures grounded in biophysics principles and integrates generative AI, predictive analytics, and computational chemistry into a single end-to-end workflow accessible at app.moleculeai.com.
Is Molecule AI a public or private company?
Molecule AI is a private company. It is classified as corporate owned and is currently acquired.
When was Molecule AI founded?
Molecule AI was founded in 2023. It employs 1 to 10 people.
Where is Molecule AI based?
Molecule AI is headquartered in New Delhi, India, in the Asia region.
How does Molecule AI make money?
Two revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are platform Usage.
Who are Molecule AI's main competitors?
Emerging players on record are Isomorphic Labs and CrushBio (Cradle Bio). Direct peers are Insilico Medicine, Schrödinger, Inc., Exscientia, XtalPi, Recursion Pharmaceuticals, Atomwise and BenevolentAI. Dassault Systèmes (BIOVIA) is listed as a broad incumbent.
Does Molecule AI have an API?
No public API is recorded for Molecule AI.
What industry is Molecule AI in?
Molecule AI's product category is AI-Driven Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714.